Clinuvel Pharmaceuticals (ASX:CUV) has enrolled more than 200 patients in its phase III trial of Scenesse in vitiligo in line with its recruitment target, according to a Wednesday filing with the Australian bourse.
The randomized trial is being conducted in 37 study sites across North America, Africa, and Europe. It is assessing Scenesse as a systemic repigmentation therapy for vitiligo patients using the vitiligo area scoring index as the primary endpoint, the filing said.
The trial aims to achieve a minimum of 50% repigmentation across a patient's total body surface area, the filing added. Initial results are expected in the second half of 2026.
Clinuvel Pharmaceuticals' shares were down nearly 1% in recent Wednesday trade.